By Josh White
Date: Friday 25 Nov 2022
LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
| Currency | UK Pounds |
| Share Price | 1.93p |
| Change Today | -0.067p |
| % Change | -3.33 % |
| 52 Week High | 4.00p |
| 52 Week Low | 1.85p |
| Volume | 134,132 |
| Shares Issued | 237.95m |
| Market Cap | £4.60m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 13:01 | 54,385 @ 1.85p |
| 11:17 | 27,272 @ 2.03p |
| 08:13 | 8,003 @ 1.90p |
| 08:00 | 44,472 @ 1.90p |
You are here: research